- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Financial analysis and consensus estimates detail the competitive GLP-1 market between Eli Lilly and Novo Nordisk.
Novo Nordisk and Eli Lilly are locked in a fierce battle for market share, with Novo shares dropping in Copenhagen and a new Wegovy pill launch planned for Germany.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk and Eli Lilly are locked in a fierce battle for market share, with Novo shares dropping in Copenhagen and a new Wegovy pill launch planned for Germany.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Novo Nordisk is seeking marketing authorization from the European Medicines Agency (EMA).
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- Novo Nordisk launched its Wegovy pill in the German market.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.